Cargando…

The effect of ligand amount, affinity and internalization on PSMA-targeted imaging and therapy: A simulation study using a PBPK model

The aim of this work was to investigate the effect of ligand amount, affinity and internalization of prostate-specific membrane antigen (PSMA)-specific ligands on the activity concentrations for PET/CT imaging and on the absorbed doses for therapy. A physiologically-based pharmacokinetic (PBPK) mode...

Descripción completa

Detalles Bibliográficos
Autores principales:	Begum, Nusrat J., Glatting, Gerhard, Wester, Hans-Jürgen, Eiber, Matthias, Beer, Ambros J., Kletting, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6934468/ https://www.ncbi.nlm.nih.gov/pubmed/31882829 http://dx.doi.org/10.1038/s41598-019-56603-8

Ejemplares similares

Influence of sampling schedules on [(177)Lu]Lu-PSMA dosimetry
por: Rinscheid, Andreas, et al.
Publicado: (2020)

Investigating the Effect of Ligand Amount and Injected Therapeutic Activity: A Simulation Study for (177)Lu-Labeled PSMA-Targeting Peptides
por: Kletting, Peter, et al.
Publicado: (2016)

A population-based method to determine the time-integrated activity in molecular radiotherapy
por: Hardiansyah, Deni, et al.
Publicado: (2021)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic Modeling Is Essential in (90)Y-Labeled Anti-CD66 Radioimmunotherapy
por: Kletting, Peter, et al.
Publicado: (2015)

[(111)In]PSMA-I&T: expanding the spectrum of PSMA-I&T applications towards SPECT and radioguided surgery
por: Schottelius, Margret, et al.
Publicado: (2015)

A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
por: Zaid, Nouran R. R., et al.
Publicado: (2021)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

Radiohybrid Ligands: A Novel Tracer Concept Exemplified by (18)F- or (68)Ga-Labeled rhPSMA Inhibitors
por: Wurzer, Alexander, et al.
Publicado: (2020)

Design of PSMA ligands with modifications at the inhibitor part: an approach to reduce the salivary gland uptake of radiolabeled PSMA inhibitors?
por: Felber, Veronika Barbara, et al.
Publicado: (2021)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

Preclinical biodistribution and dosimetry and human biodistribution comparing (18)F-rhPSMA-7 and single isomer (18)F-rhPSMA-7.3
por: Knorr, Karina, et al.
Publicado: (2022)

Comparison of Quantification of Target-Specific Accumulation of [(18)F]F-siPSMA-14 in the HET-CAM Model and in Mice Using PET/MRI
por: Löffler, Jessica, et al.
Publicado: (2021)

PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy
por: Wang, Hui, et al.
Publicado: (2021)

Single-time-point dosimetry using model selection and nonlinear mixed-effects modelling: a proof of concept
por: Hardiansyah, Deni, et al.
Publicado: (2023)

Single-time-point estimation of absorbed doses in PRRT using a non-linear mixed-effects model
por: Hardiansyah, Deni, et al.
Publicado: (2022)

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
por: Weineisen, Martina, et al.
Publicado: (2014)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

Impact of the mouse model and molar amount of injected ligand on the tissue distribution profile of PSMA radioligands
por: Tschan, Viviane J., et al.
Publicado: (2021)

Optimization of Radiolabeling of a [(90)Y]Y-Anti-CD66-Antibody for Radioimmunotherapy before Allogeneic Hematopoietic Cell Transplantation
por: Winter, Gordon, et al.
Publicado: (2023)

(68)Ga-PSMA ligand PET/CT in patients with prostate cancer: How we review and report
por: Rauscher, Isabel, et al.
Publicado: (2016)

[(99cm)Tc]Tc-PSMA-I&S-SPECT/CT: experience in prostate cancer imaging in an outpatient center
por: Werner, P., et al.
Publicado: (2020)

Current Staging Procedures in Urinary Bladder Cancer
por: Maurer, Tobias, et al.
Publicado: (2013)

PSMA-targeted imaging of prostate cancer: evolution of a success story
por: Maurer, Tobias, et al.
Publicado: (2017)

PET Imaging of Integrin αVβ3 Expression
por: Beer, Ambros J., et al.
Publicado: (2011)

Synthesis and Preclinical Evaluation of (177)Lu-Labeled Radiohybrid PSMA Ligands for Endoradiotherapy of Prostate Cancer
por: Wurzer, Alexander, et al.
Publicado: (2022)

Synthesis and preclinical evaluation of novel (99m)Tc-labeled PSMA ligands for radioguided surgery of prostate cancer
por: Kunert, Jan-Philip, et al.
Publicado: (2023)

PBPK modeling and simulation in drug research and development
por: Zhuang, Xiaomei, et al.
Publicado: (2016)

PSMA-PET und „radio-guided surgery“ bei zervikaler Lymphadenektomie
por: Lingl, Julia P., et al.
Publicado: (2022)

Enzalutamide Enhances PSMA Expression of PSMA-Low Prostate Cancer
por: Staniszewska, Magdalena, et al.
Publicado: (2021)

Dependence of treatment planning accuracy in peptide receptor radionuclide therapy on the sampling schedule
por: Maaß, Christian, et al.
Publicado: (2016)

Microtiter plate-based antibody-competition assay to determine binding affinities and plasma/blood stability of CXCR4 ligands
por: Harms, Mirja, et al.
Publicado: (2020)

Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model
por: Kuepfer, L, et al.
Publicado: (2016)

Quantitative analysis of regional distribution of tau pathology with (11)C-PBB3-PET in a clinical setting
por: Yousefzadeh-Nowshahr, Elham, et al.
Publicado: (2022)

Pitfalls in PSMA imaging: [(18)F]rhPSMA-7-PET/CT reveals presence of chrondrosarcoma
por: Feuerecker, B., et al.
Publicado: (2021)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

A rare case of polyostotic fibrous dysplasia detected on (18)F-rhPSMA-7 PET/CT
por: Wang, Hui, et al.
Publicado: (2020)

Automated synthesis of [(18)F]Ga-rhPSMA-7/ -7.3: results, quality control and experience from more than 200 routine productions
por: Wurzer, Alexander, et al.
Publicado: (2021)

Efficacy of PSMA ligand PET-based radiotherapy for recurrent prostate cancer after radical prostatectomy and salvage radiotherapy
por: Oehus, Ann-Kathrin, et al.
Publicado: (2020)

Synthesis and Preclinical Characterization of the PSMA-Targeted Hybrid Tracer PSMA-I&F for Nuclear and Fluorescence Imaging of Prostate Cancer
por: Schottelius, Margret, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ao546jgmm5gcu1efvuarsm81gs